<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33403">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826019</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE-4</org_study_id>
    <nct_id>NCT01826019</nct_id>
  </id_info>
  <brief_title>Heart Outcomes Prevention and Evaluation 4</brief_title>
  <acronym>HOPE-4</acronym>
  <official_title>Heart Outcomes Prevention and Evaluation 4 (HOPE-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grand Challenges Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Alliance for Chronic Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cadila Pharmaceuticals Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <authority>Colombia: Ministry of Health and Social Protection</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the HOPE-4 study, Phases (hypertension (HT) and cardiovascular
      disease (CVD)), is to develop and test a program for cardiovascular disease risk assessment
      and treatment involving: (1) simple screening and treatment guidelines implemented by
      non-physician health workers (NPHW); (2) single pill containing blood pressure and
      cholesterol lowering drugs; and (3) family or friends and mobile phone technology to help
      participants comply with the treatment regimen. This program has the potential to reduce
      major cardiovascular events by 35% over 6 years, as compared to usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: open-label, cluster randomized controlled trial design.

      HT Phase: 50 urban and rural communities in Colombia and Malaysia will be randomized to
      participate in an intensive cardiovascular (CV) risk detection and control program by
      non-physician health workers (NPHW) or to care as usual for 12 months.

      CVD Phase: Continuation and expansion of HT Phase to include a total of 190 urban and rural
      communities in countries within Asia (India, Malaysia, Philippines), South America
      (Colombia, Argentina), and Sub-Saharan Africa (South Africa, Tanzania, Rwanda) that will be
      allocated to participate in the intensive CV risk detection and control program by NPHW or
      to care as usual for a target of 6 years.

      Communities will be randomized 1:1 with a central randomization list to either a)
      intervention or b) control.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The mean difference in change in systolic blood pressure (BP) between the intervention and control communities from baseline to 1 year.</measure>
    <time_frame>Baseline to 1 year (HT phase)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in a composite of major CV events [(CV death, MI, stroke, congestive heart failure (CHF) and CV hospitalizations (e.g. AF, unstable or new onset angina, CHF, arterial revascularization), and end-stage renal disease] from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean differences in calculated INTERHEART risk score from baseline to 1 year.</measure>
    <time_frame>Baseline to 1  year (HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in the proportion of participants on antihypertensive treatment and well-controlled from baseline to 1 year.</measure>
    <time_frame>Baseline to 1 year (HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of initiations, discontinuations, and up/down titrations of PolyCap formulations, as well as number of hospitalizations and CVD events from baseline to 1 year.</measure>
    <time_frame>Baseline to 1 year (HT Phase)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the individual components of the primary outcome from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in systolic BP, HDL, and LDL from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in calculated lab and non-lab based INTERHEART Risk Score from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of initiations, discontinuations, and up/down titrations of PolyCap formulations from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in systolic BP from baseline to 6 months</measure>
    <time_frame>Baseline to 6 months(HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean differences in calculated non-lab based INTERHEART risk score from baseline to 6 months</measure>
    <time_frame>Baseline to 6 months(HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in the proportion of participants on antihypertensive treatment and well-controlled from baseline to 6 months.</measure>
    <time_frame>Baseline to 6 months (HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in HDL and LDL values from baseline to 1 year.</measure>
    <time_frame>Baseline to 1 year (HT Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of hypertension related emergencies reported from baseline to 6 years.</measure>
    <time_frame>Baseline to 6 Years (CVD Phase)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Health economic evaluations - measure/calculate the unit costs and the quantity used of each of the components of the intervention and in usual care in the participating countries.</measure>
    <time_frame>Baseline to 6 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will collect data that will allow us to determine (i) the costs of the suggested programs (i.e. intervention package) and the costs of what is being provided currently for CVD assessment and management in the communities studied (i.e. control).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9500</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive CV risk detection, counselling and follow-up program by non-physician health workers (NPHW); open-label fixed-dose combination pill therapy (Polycap) in accordance with treatment algorithm; use of treatment supporters and mobile phone technology to reinforce adherence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Usual Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in control communities will be referred to usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>In intervention communities, management plans will be developed by the NPHW for all enrolled participants.  The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate.   Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Standard and half-dose Polycap formulations will be provided to the NPHWs and supervising physicians for participant treatment.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.</description>
    <arm_group_label>Control - Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 50 years of age

          -  systolic blood pressure (SBP) 140-159 mmHg on 2 separate visits (&gt;= 24 hours between
             visits)

          -  SBP &gt; 160 mmHg on one visit

          -  SBP &lt; 140 mmHg but a confirmed history of HT and taking anti-HT medications

          -  Reported history of diabetes, myocardial infarction (MI), cerebrovascular accident
             (CVA), coronary artery bypass surgery or coronary angioplasty (+/- stent):
             participant reported history of clinical diagnosis

          -  Angina: participant-reported history of clinical diagnosis PLUS at least one of the
             following:

               -  Definite angina (sub-sternal chest pain that is provoked by exertion (exercise
                  or stress) and is relieved by rest or nitroglycerin OR

               -  Prescription of beta blockers, nitrates, calcium channel blockers or other
                  antianginal drugs OR

          -  Congestive heart failure (CHF): participant-reported history of clinical diagnosis
             PLUS at least one of the following:

               -  Total score of â‰¥ 5 points (rest dyspnea (4 points), orthopnea (4 points),
                  paroxysmal nocturnal dyspnea (3 points), dyspnea on flat surface (2 points),
                  dyspnea on climbing (1 point) OR

               -  Prescription of furosemide (or similar loop diuretic)

        General Exclusion Criteria:

          -  Refusal to Consent

          -  Actively involved in any study that would compromise the protocol of HOPE-4

          -  Severe co-morbid condition with life expectancy &lt; 1 year

          -  Other serious condition(s) or logistic factors likely to interfere with study
             participation or with the ability to complete the trial

        Polycap Exclusion Criteria:

          -  Participants with a clear contraindication or intolerance to statin, beta blocker, or
             diuretic in the judgment of the physician

          -  Participants with chronic liver disease or abnormal liver function (i.e. Alanine
             transaminase (ALT) or aspartate aminotransferase (AST) &gt; 3x upper limit of normal
             (ULN))

          -  Inflammatory muscle disease (such as dermatomyositis or polymyositis) or creatine
             kinase (CK) &gt; 3x ULN

          -  Severe renal impairment (serum creatinine &gt; 200 umol/L)

          -  Potassium (K) &gt; 5.5 mmol/L
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon-David Schwalm, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and Hamilton Health Sciences Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim Yusuf, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and Hamilton Health Sciences Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara L McCready, PhD, MBA</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40439</phone_ext>
    <email>tara.mccready@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Population Health Research Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.phri.ca</url>
    <description>Population Health Research Institute</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
